Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2017 | How durable are the responses of CLL patients to therapy?

Peter Hillmen • 14 Aug 2017
iwCLL 2017
Chronic Lymphocytic Leukemia Ibrutinib Venetoclax

Peter Hillmen, MD, PhD, from the University of Leeds, Leeds, UK, talks to us about the need to determine the durability of chronic lymphocytic leukemia (CLL) patients’ responses off-treatment. He notes that there is difficulty in doing so due to individual patients having differing response rates. This video was recorded at the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2017 in New York, NY.

More from Peter Hillmen

1:55
Key updates from the interim analysis of the FLAIR trial
Peter Hillmen • 10 Jun 2022
1:03
CLL trial updates from EHA 2022
Peter Hillmen • 10 Jun 2022
1:19
Acalabrutinib vs ibrutinib in previously untreated high-risk CLL
Peter Hillmen • 10 Jun 2022
1:40
The role of MRD in decision-making in CLL
Peter Hillmen • 10 Jun 2022

Related Videos

3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
0:44
Early detection and interception across hematological cancers
Irene Ghobrial • 8 Apr 2024
1:21
Monoclonal B-cell lymphocytosis: a disease to be (or not to be)
Paolo Ghia • 7 Apr 2024
The content of VJHemOnc is intended for healthcare professionals